Cyclophosphamide (generic), Cytoxan Newswire (Page 5)

Cyclophosphamide (generic), Cytoxan Newswire (Page 5)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 5)

Results 81 - 100 of 919 in Cyclophosphamide (generic), Cytoxan

  1. Immunotherapy drug combination shows prominent therapeutic effect...Read the original story w/Photo

    Jul 12, 2016 | Medical News

    A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget.

    Comment?

  2. FDA places hold on clinical trial of cancer treatment previously reported on KurzweilAIRead the original story w/Photo

    Jul 12, 2016 | KurzweilAI.net

    Juno Therapeutics, Inc. announced July 7 that it has received notice from the FDA that it has placed a clinical hold on an immune-cell cancer treatment known as the "ROCKET" trial, which was reported on KurzweilAI on Mar. 10, 2016. The clinical hold was initiated after two patient deaths, which followed the recent addition of fludarabine to the pre-conditioning regimen.

    Comment?

  3. A Big Blow to CAR-T -- Should Investors Buy?Read the original story w/Photo

    Jul 9, 2016 | The Motley Fool

    After two more people passed away in a key clinical trial of a next-generation cancer-fighting approach, shares in Juno Therapeutics lost roughly a third of their value. The deaths have resulted in the FDA placing the trial on hold; but it's too soon to say whether or not that hold will remain in place for long.

    Comment?

  4. Cancer therapy study halted after patient deathsRead the original story w/Photo

    Jul 9, 2016 | Fox News

    A Juno Therapeutics Inc trial of its experimental cancer therapy , known as JCAR015, was put on hold by U.S. regulators after the deaths last week of two leukemia patients, the company said on Thursday. Shares of Juno fell 30 percent to $28.50 in after-hours trading on the Nasdaq after they closed at $40.82.

    Comment?

  5. Cancer immunotherapy trial halted after patient deathsRead the original story w/Photo

    Jul 8, 2016 | UPI

    A clinical trial for a new immunotherapy drug for leukemia was halted by the U.S. Food and Drug Administration after two patients died last week, the company developing the drug reported this week. Juno Therapeutics stopped its phase 2 "ROCKET" trial for JCAR015 under instruction from the FDA after the two recent deaths, which follow another earlier this year -- though the company hopes to restart the trial after making changes to how the drug is delivered.

    Comment?

  6. Patient Deaths Halt Cancer StudyRead the original story

    Jul 8, 2016 | P&T Community

    The FDA has placed a clinical hold on a phase 2 trial of JCAR015 , a chimeric antigen receptor T-cell therapy, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia . The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the preconditioning regimen.

    Comment?

  7. FDA halts cancer immunotherapy trial after 3 patient deathsRead the original story w/Photo

    Jul 8, 2016 | WTVR Richmond

    Following two patient deaths last week and another earlier this year, Juno Therapeutics announced Thursday that it is putting its "ROCKET" trial on clinical hold, at the direction of the U.S. Food and Drug Administration. The patients enrolled in this Phase II trial are adults with relapsed or refractory B cell acute lymphoblastic leukemia, according to the biopharmaceutical company's website.

    Comment?

  8. U.S. cancer drug trial halted after three test subjects die after taking drug to reprogram T-cellsRead the original story w/Photo

    Jul 8, 2016 | National Post

    The U.S. Food and Drug administration has forced a pharmaceutical company to halt clinical trials of an experimental cancer drug after three patients died while undergoing treatment. Juno Therapeutics, a Seattle-based biotechnology company started in 2013, was testing the new treatment called JCAR015, also known as the ROCKET trial.

    Comment?

  9. Kite Pharma Completes Enrollment Of All Patients With Diffuse Large...Read the original story

    Jul 7, 2016 | BioSpace

    Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy products for the treatment of cancer, announced today that it has completed enrollment of 72 patients in DLBCL cohort in the Phase 2 portion of ZUMA-1. KTE-C19 is an investigational therapy in which a patient's T-cells are genetically modified to express a chimeric antigen receptor that is designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.

    Comment?

  10. Juno Therapeutics (JUNO) Stock Downgraded at JPMorganRead the original story w/Photo

    Jul 8, 2016 | TheStreet.com

    Juno Therapeutics' stock rating was slashed to "neutral" from "overweight" at JPMorgan after the biopharmaceutical company's phase 2 clinical trial was put on clinical hold by the FDA after patient deaths. Juno reminds investors that the business of biotech, developing new medicines that are effective and reasonable safe, is hard to get right, TheStreet's Adam Feuerstein wrote in an article this morning.

    Comment?

  11. Juno Therapeutics Price Target Cut From $63 To $39 At JPMorganRead the original story

    Jul 8, 2016 | Benzinga

    Juno Therapeutics Inc has placed its lead CAR-T [pivotal Phase 2 ROCKET trial evaluating JCAR015 in adult ALL] on clinical hold after 2 patient deaths. JPMorgan's Cory Kasimov downgraded the rating on the company from Overweight to Neutral, while raising the price target from $63 to $39.

    Comment?

  12. Juno cancer study halted after patient deathsRead the original story w/Photo

    Jul 8, 2016 | Fox News

    A Juno Therapeutics Inc trial of its experimental cancer therapy , known as JCAR015, was put on hold by U.S. regulators after the deaths last week of two leukemia patients, the company said on Thursday. Shares of Juno fell 30 percent to $28.50 in after-hours trading on the Nasdaq after they closed at $40.82.

    Comment?

  13. Cary community supports infant pediatric cancer patientRead the original story w/Photo

    Jul 7, 2016 | Northwest Herald

    McKai was diagnosed with rhabdomyosarcoma, a type of cancer that grows in muscle and soft tissue. The drug he takes cyclophosphamide is one of the most toxic to the male reproductive system.

    Comment?

  14. Juno Crashes After Cancer Trial Halted Following Two DeathsRead the original story

    Jul 7, 2016 | BioSpace

    Juno Therapeutics, Inc. , a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia , known as the "ROCKET" trial. The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen.

    Comment?

  15. Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL)...Read the original story w/Photo

    Jul 7, 2016 | Freshnews

    Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy products for the treatment of cancer, announced today that it has completed enrollment of 72 patients in DLBCL cohort in the Phase 2 portion of ZUMA-1. KTE-C19 is an investigational therapy in which a patient's T-cells are genetically modified to express a chimeric antigen receptor that is designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.

    Comment?

  16. Juno cancer study halted after patient deaths, shares slide 30 pctRead the original story w/Photo

    Jul 7, 2016 | Reuters

    A Juno Therapeutics Inc trial of its experimental cancer therapy, known as JCAR015, was put on hold by U.S. regulators after the deaths last week of two leukemia patients, the company said on Thursday. Shares of Juno fell 30 percent to $28.50 in after-hours trading on the Nasdaq after they closed at $40.82.

    Comment?

  17. Juno Therapeutics Reports Clinical Hold on the JCAR015 Phase II Rocket TrialRead the original story w/Photo

    Jul 7, 2016 | Freshnews

    Juno Therapeutics, Inc. , a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia , known as the "ROCKET" trial. The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen.

    Comment?

  18. Juno Stock Plummets in After-Hours Trading, Clinical Trial Put on Hold After 2 DeathsRead the original story w/Photo

    Jul 7, 2016 | TheStreet.com

    Shares of Juno Therapeutics are plunging 27.85% to $29.45 in after-hours trading Thursday after the FDA put a cancer drug on a phase 2 clinical hold after two patients involved in the trial died last week. The Seattle-based biopharmaceutical company said the deaths followed the recent addition of chemotherapy drug fludarabine to the pre-conditioning regimen.

    Comment?

  19. Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer DrugRead the original story w/Photo

    Jul 7, 2016 | Benzinga

    Juno Therapeutics Inc was halted shortly after Thursday's closing bell. A couple minutes later, the company announced JCAR015's Phase 2 trial was put on hold after two patients died last week.

    Comment?

  20. Juno's mid-stage study of lead CAR-T candidate on clinical hold after ...Read the original story w/Photo

    Jul 7, 2016 | Seeking Alpha

    Juno Therapeutics' Phase 2 clinical trial, ROCKET, assessing lead CAR-T candidate JCAR015 in adult patients with relapsed/refractory B cell acute lymphoblastic leukemia has been placed on clinical hold by the FDA after two study participants died last week following the recent addition of chemo agent fludarabine to the pre-conditioning regimen. The company has proposed continuing the study using JCAR015 with cyclophosphamide pre-conditioning alone.

    Comment?